Iron is an essential component of the erythrocyte protein hemoglobin and is crucial to oxygen transport in vertebrates. In the steady state, erythrocyte production is in equilibrium with erythrocyte removal 1 . In various pathophysiological conditions, however, erythrocyte life span is compromised severely, which threatens the organism with anemia and iron toxicity 2, 3 . Here we identify an on-demand mechanism that clears erythrocytes and recycles iron. We show that monocytes that express high levels of lymphocyte antigen 6 complex, locus C1 (LY6C1, also known as Ly-6C) ingest stressed and senescent erythrocytes, accumulate in the liver via coordinated chemotactic cues, and differentiate into ferroportin 1 (FPN1, encoded by SLC40A1)-expressing macrophages that can deliver iron to hepatocytes. Monocytederived FPN1 + Tim-4 neg macrophages are transient, reside alongside embryonically derived T cell immunoglobulin and mucin domain containing 4 (Timd4, also known as Tim-4) high Kupffer cells (KCs), and depend on the growth factor Csf1 and the transcription factor Nrf2 (encoded by Nfe2l2). The spleen, likewise, recruits iron-loaded Ly-6C high monocytes, but these do not differentiate into iron-recycling macrophages, owing to the suppressive action of Csf2. The accumulation of a transient macrophage population in the liver also occurs in mouse models of hemolytic anemia, anemia of inflammation, and sickle cell disease. Inhibition of monocyte recruitment to the liver during stressed erythrocyte delivery leads to kidney and liver damage. These observations identify the liver as the primary organ that supports rapid erythrocyte removal and iron recycling, and uncover a mechanism by which the body adapts to fluctuations in erythrocyte integrity.
The physiological 120-day lifespan of human erythrocytes (red blood cells, RBCs) 4, 5 is shortened in various pathologies [6] [7] [8] [9] [10] . Red blood cell production requires a sufficient supply of iron: when iron stores are low, erythrocytes cannot be produced efficiently, causing anemia and tissue hypoxia. Because iron is acquired poorly through diet, most of the daily amount of iron needed for erythropoiesis is recycled by the reticuloendothelial system in the spleen and liver in a process that depends on the transmembrane iron export protein FPN1 (refs. 1, 11, 12) . Disease-associated erythrocyte damage threatens the organism in several ways: (i) damaged erythrocytes release hemoglobin and heme, which can cause acute kidney injury; (ii) erythrocyte loss leads to anemia; and (iii) the heightened need for erythrophagocytosis may overwhelm physiologic erythrocyte-clearing capacities, thereby liberating large quantities of iron, which is toxic in its nontransferrin-bound form 1 . We therefore hypothesized that vertebrates have evolved mechanisms that can adapt to fluctuations in erythrocyte integrity.
Erythrocytes and leukocytes can be identified as lymphocyte antigen 76 (Ly76, also known as Ter119) + CD45 − and Ter119 − CD45 + cells, respectively (Supplementary Fig. 1a ). Labeling erythrocytes with a membrane-integrating dye (PKH26) ex vivo enabled detection in vivo and the tracking of labeled cells (Fig. 1a) . Whereas most 'young' erythrocytes circulated in host blood for at least 16 h, aged or stressed erythrocytes (sRBCs) 13, 14 quickly disappeared ( Supplementary  Fig. 1b) . Stressed erythrocytes co-localized with leukocytes predominantly in the liver (Fig. 1b) , but also in the spleen, bone marrow, blood, and lung. Although splenectomized mice had higher percentages of delivered erythrocytes in the circulation then did nonsplenectomized controls, near-complete hepatectomy (95%) resulted in pronounced erythrocyte persistence in the circulation, and splenectomy combined with near-complete hepatectomy had the greatest effect on the persistence of damaged RBCs in the blood (Fig. 1c,d and Supplementary Fig. 2a ).
In the steady state, the liver contains abundant F4/80 high CD11b int KCs and relatively few CD11b high cells (Fig. 1e) . The injection of stressed erythrocytes led to dramatic leukocyte fluctuations in the liver. At 3 h after sRBC injection, monocyte numbers peaked ( Fig. 1f) . At 16 h, a population of CD11b high F4/80 high macrophages (henceforth called transient macrophages (tMΦs)) appeared in the liver (Fig. 1e,f 
),
On-demand erythrocyte disposal and iron recycling requires transient macrophages in the liver but the number of F4/80 high CD11b int KCs was diminished. At 72-168 h, the populations returned to near-basal levels (Fig. 1e,f) . The spleen, which contains F4/80 high CD11b int red pulp macrophages (RPMs) and monocytes, accumulated monocytes, but hardly any tMΦs, after stressed erythrocyte challenge ( Fig. 1e,f) . tMΦ accumulation in the liver was a specific response to the injection of hemoglobin-containing erythrocytes; the injection of hemoglobin-depleted 'ghosts' did not induce the appearance of tMΦs ( Fig. 1e) .
We used two independent approaches to track sRBC uptake by leukocytes. First, flow cytometry and histology detected PKH26 fluorescence in gated and sorted leukocyte populations, respectively, as a surrogate for sRBC ingestion (Supplementary Figs. 2b-d and  3) . In the blood, Ly-6C high monocyte ingestion of sRBCs peaked 1 h after challenge, and sRBC-laden monocytes ( Supplementary Fig. 4a ) subsequently accumulated in the liver and spleen ( Supplementary  Fig. 4b,c) . At 16 h, tMΦs in the liver contained the largest proportion of sRBCs ( Fig. 1g and Supplementary Fig. 4b,c) . No tMΦs appeared in the spleen, bone marrow, kidney, or lung ( Supplementary  Fig. 4d ). Immunofluorescence substantiated these observations ( Fig. 1h and Supplementary Fig. 2b,c) . Second, we measured iron content in sorted leukocytes by atomic absorption spectroscopy and confirmed that tMΦs in the liver contained the bulk of the iron ( Fig. 1i) , presumably because of their ingestion of sRBCs. Such ingestion was probably mediated by receptors such as macrophage-scavenging receptor 1 (Msr1, also known in humans as SR-A) and CD36, because mice deficient in those receptors did not scavenge sRBCs as efficiently as WT controls ( Supplementary Fig. 5a ,b) 15 . The spleen was dispensable to the appearance of tMΦs in the liver ( Supplementary  Fig. 5c ), whereas lethal irradiation, which depleted monocytes without affecting KC or RPM numbers at 10 d after irradiation, impaired erythrocyte clearance ( Supplementary Fig. 5d-f ). Shortly after stressed erythrocyte challenge, we detected erythrophagocytosing macrophages by scanning electron microscopy ( Fig. 1j) . At 16 h, we observed a punctate pattern of iron stores, consistent with the confinement of iron in macrophages ( Supplementary  Fig. 6a ). By 1 week after challenge, however, iron appeared in a diffuse parenchymal pattern, which is indicative of its accumulation in hepatocytes ( Supplementary Fig. 6a ). The greatest increase in iron levels at 16 h occurred in the liver (Supplementary Fig. 6b ). This increase corresponded to high levels of liver hepcidin ( Supplementary Fig. 6b ), which is produced by hepatocytes in response to iron accumulation and is therefore a good marker of iron load in the liver 1, 4, 16 . To test whether the appearance of tMΦs was a general response to the increased demand for erythrophagocytosis, (e) Top, scheme for the formal lineage-tracing experiments in which Cx3cr1 CreERT2 females were crossed with R26-tdT males. Bottom, flow-cytometry plots of liver leukocytes depicting embryonically derived tdT + KC (eKC) and GFP + mKCs appearing after sRBC challenge. (f) Wholegenome expression profiling in mKCs and eKCs (n = 3 per group). Volcano plot depicts −log 10 Benjamini-Hochberg-corrected P value versus log 2 foldregulation for each gene. Genes whose mRNA levels were significantly augmented (P Benjamini-Hochberg < 0.1 and fold regulation > 1.5) in mKCs or eKCs are highlighted in green and red, respectively. (g) Tim-4 cell surface expression in liver KCs and monocytes at steady state (0 h) and 7 d after sRBC injection. Representative dot plots (one of three experiments). npg VOLUME 22 | NUMBER 8 | AUGUST 2016 nature medicine we used three anemia models: a model of hemolytic anemia induced by phenylhydrazine (PHZ) delivery 17, 18 ; a model of anemia of inflammation induced by heat-inactivated Brucella abortus 19, 20 ; and a model of sickle cell anemia 21 . In each model we detected tMΦ accumulation in the liver, but not in the spleen (Supplementary Fig. 7) . In humans, erythrocyte damage resulted in erythrocyte accumulation in circulating CD14 high CD16 − monocytes, as assessed by detection of the erythrocyte marker CD235a (encoded by GYPA) ( Supplementary  Fig. 8a,b ) and by measurements of iron content inside monocytes ( Supplementary Fig. 8c ). Monocyte ingestion of erythrocytes was associated with increased serum iron levels and decreased serum haptoglobin levels relative to the steady state ( Supplementary Fig. 8d,e )
Macrophage-ingested iron is either stored in the cytoplasm bound to ferritin or is exported via FPN1 (ref. 11). Ferritin and FPN1 were expressed in both the spleen and liver in the steady state (Supplementary Fig. 9a-c) , as expected 17, 18 . Among leukocyte populations, KCs and RPMs expressed FPN1 on their surfaces ( Fig. 2a) for iron transport, as assessed by an iron-release assay ( Supplementary  Fig. 9d ). However, the transfusion of stressed, iron-containing erythrocytes resulted in increased expression of FPN1 in the liver, but not in the spleen, as compared to steady-state controls ( Fig. 2a and Supplementary Fig. 9a-c) , and led to increased FPN1 surface expression on tMΦs, specifically in the liver (Fig. 2a) . The appearance of tMΦs in the liver required the injection of intact stressed erythrocytes (Supplementary Fig. 9e ) and was exacerbated in response to competitive inhibition of the heme-cleaving enzyme heme oxygenase (Hmox) 1 by tin-protoporphyrin IX (SnPP-IX) ( Supplementary Fig. 9f ). These results suggest that the liver is uniquely mechanistically equipped to respond to an increased demand for erythrophagocytosis.
Given the phenotypic similarities between monocytes and tMΦs, we tested whether Ly-6C high monocytes give rise to FPN1 + tMΦs in the liver. We adoptively transferred GFP + Ly-6C high or Ly-6C low monocytes to mice receiving stressed erythrocytes. Immediately after transfer, both monocyte subsets circulated in the blood, but neither produced FPN1 (Fig. 2b) . 16 h later, Ly-6C high monocytes expressing F4/80 appeared in the liver, thus resembling tMΦs (Fig. 2b) . By 72 h, these Ly-6C high monocyte-derived tMΦs had further differentiated to resemble KCs; they still contained erythrocytes (or their remnants) and still expressed FPN1 and the classical macrophage npg signature proteins 22 Mertk and CD64 (encoded by Fcgr1) on their surfaces (Fig. 2b) . By contrast, Ly-6C low monocytes infiltrated the liver in lower numbers than did Ly-6C high monocytes, did not differentiate to tMΦs, and remained FPN1 − , Mertk − , and CD64 − ( Fig. 2b and Supplementary Fig. 9g) . Moreover, monocyte-to-FPN1 + macrophage differentiation was specific to the liver, and only a few of the transferred cells from either subset accumulated in the spleen (Fig. 2b) . We observed a similar phenomenon after transferring GFP + Ly-6C high monocytes to sickle-cell-disease model mice (Supplementary Fig. 10a,b) .
To test whether Ly-6C high monocytes can support long-term KC renewal or whether tissue-derived KCs eventually outcompete monocyte-derived cells, we joined C57BL/6 and GFP + mice by parabiosis ( Supplementary Fig. 10c,d) 23 . In the absence of erythrocyte delivery, Ly-6C high blood monocyte chimerism rose to ~25% in the first 2 weeks and remained unchanged for >100 d, whereas KC chimerism remained low, at <2%, for the duration of the experiment (Fig. 2c) . Erythrocyte delivery 2 weeks after parabiosis began had no effect on blood monocyte chimerism, but it increased chimerism among KCs to ~15% for >28 d (Fig. 2c) . By contrast, RPM chimerism did not rise in the spleen as a consequence of erythrocyte challenge. These data show that a high demand for erythrophagocytosis mobilizes erythrocyte-ingesting Ly-6C high monocytes to the liver, where they first differentiate to iron-recycling tMΦs and then to iron-recycling KC-like cells. When demand declines, monocytederived KC-like cells disappear, and the remaining KC replenish, independently of monocytes or other circulating progenitors.
To dig deeper into how monocyte and tissue-derived macrophages differ, we sorted liver KCs and tMΦs 16 h after erythrocyte challenge into groups that either had or had not ingested erythrocytes. We then profiled gene expression by RT-PCR ( Fig. 2d) and surface protein expression by flow cytometry (Supplementary Fig. 10e) , detecting numerous differences, including the expression of Spic, which encodes a transcription factor required for RBC recycling 17, 18 . Next, because increased KC chimerism after erythrocyte challenge (Fig. 2c) , as well as a shift of tMΦs to the KC gate (Fig. 2b) , indicated that, for a limited time, KCs are a mixed population composed of both tissue-and blood-derived cells, we performed formal lineagetracing experiments. We mated Cx3cr1 CreERT2 females with ROSA26-tdTomato fl/fl (R26-tdT) males 24, 25 , giving rise to Cx3cr1 CreERT2 ; R26-tdT pups with tdT + KCs and tdT − monocytes ( Fig. 2e) . On postnatal (P) day 70, we transplanted GFP + bone marrow to generate GFP + monocytes in the grown pups ( Fig. 2e and Supplementary Fig. 11a) . On day P91, we challenged the mice with stressed erythrocytes and, 7 d later, detected embryonically derived tdT + GFP − KCs (eKCs) and monocyte-derived tdT − GFP + KCs (mKCs) in the KC gate. We then sorted these cells for microarray analysis (Fig. 2e) . Our data showed numerous differences between the cells ( Fig. 2f and Supplementary  Fig. 11b ), although the expression of iron metabolism mediators was comparable (Supplementary Fig. 11b,c) . Among the differentially expressed genes, Timd4, which produces the surface Tim-4 protein, was highly expressed in embryonic but not monocyte-derived KCs (Fig. 2f) , a finding that we confirmed by flow cytometry (Fig. 2g) . npg These data show that as tMΦs temporarily shift to the KC gate, they nevertheless differ from their embryonically derived counterparts. The growth factors colony stimulating factor (Csf)-1 and Csf2 instruct myeloid cell fate decisions 26, 27 . After erythrocyte challenge, the liver and spleen had augmented Csf1 expression ( Fig. 3a) , the spleen, but not liver, had augmented Csf2 expression ( Fig. 3b) , the lung had augmented expression of neither Csf1 nor Csf2 (Supplementary  Fig. 12a) , and the bone marrow had augmented Csf2 expression ( Supplementary Fig. 12b) . Consequently, the liver had a high Csf1-to-Csf2 ratio, whereas the spleen and bone marrow had a low Csf1-to-Csf2 ratio ( Fig. 3c and Supplementary Fig. 12b) , after stressed erythrocyte injection. To evaluate whether these two growth factors cultivate the selective appearance of iron-recycling macrophages, we first performed experiments in vitro. Ly-6C high monocytes (Fig. 3d)- and their human counterparts, CD14 high CD16 − monocytes (Fig. 3e) cultured in a Csf1-rich environment amplified FPN1 in response to sRBCs, whereas culture with Csf2 suppressed it (Fig. 3f) . This antagonism was specific to monocytes, given that cultured RPMs retained FPN1 in the presence of Csf2 (Supplementary Fig. 12c ). KCs were the dominant source of Csf1 in vivo (Supplementary Fig. 12d) , and Csf1-driven FPN1 augmentation was specific to Ly-6C high , when compared to Ly-6C low , monocytes (Supplementary Fig. 12e) .
The transcription factor Nrf2 recognizes heme groups and facilitates FPN1 transcription 28, 29 . In the absence of Nrf2, Csf1 failed to stimulate FPN1 production on Ly-6C high monocytes (Fig. 3g) , which indicates that Csf1-dependent FPN1 enhancement requires Nrf2. To confirm this finding in vivo, we delivered erythrocytes into either wild-type mice receiving a Csf1 inhibitor or to Nrf2 −/− mice. In both cases, FPN1 + tMΦs failed to arise in the liver, despite the appearance of F4/80 high and CD11b high cells (Fig. 3h) . FPN1 expression on KCs similarly required Nrf2, but unlike on tMΦs, FPN1 expression on KCs was unaffected by Csf1 blockade (Fig. 3i) . To determine whether Csf2 can suppress the appearance of tMΦs in vivo, we also delivered erythrocytes into Csf2 −/− mice. In the absence of Csf2, FPN1 + tMΦs appeared in the spleen, concomitantly with augmented expression of mediators of iron metabolism (Supplementary Fig. 13) . These data show that Nrf2 and Csf1 guide the production and maintenance of iron-recycling macrophages in the liver, whereas Csf2 antagonizes iron recycling in the spleen under stress.
Because the liver selectively accumulated monocyte-derived tMΦs, we surmised that chemokines guide monocytes to this organ. Expression of the chemokines Ccl2 and Ccl3 strongly increased after erythrocyte delivery in the liver, but not in the spleen (Fig. 4a) , whereas the expression of Ccl21 decreased in the spleen but not in the liver (Supplementary Fig. 14a) . Changes in the expression of other chemokines were less pronounced (Supplementary Fig. 14) . As compared to erythrocyte delivery without antagonists, the injection of Ccr2 and Ccr5 antagonists in conjunction with stressed erythrocyte delivery reduced Ly-6C high monocyte and tMΦ populations in the liver, but not in the spleen or blood, while increasing the number of monocytes in the bone (Fig. 4b) , which indicates impaired monocyte mobilization and recruitment. Accordingly, the antagonists boosted the number of circulating stressed erythrocytes in the blood, indicative of impaired clearance (Fig. 4c) .
By using these antagonists, we discovered that, compared to controls, interference with on-demand monocyte recruitment increased enhanced labile plasma iron (eLPI) levels (Fig. 4d) , which suggests that impaired clearance of stressed erythrocytes by monocyte-derived tMΦs leads to a build up in the circulation of tissue-damaging iron, heme, and hemoglobin. In support of this, we detected heightened production of haptoglobin and hemopexin in the liver (Fig. 4e) and higher levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), amylase, and blood urea nitrogen (BUN) (Fig. 4f) . The number of tMΦs in the liver was inversely correlated with eLPI, AST, and BUN (Supplementary Fig. 15 ). Moreover, we saw increased iron deposition and nephron damage in the kidney ( Fig. 4g and Supplementary Fig. 16a) . We observed similar nephron damage after Hmox1 inhibition, which is predicted to result in heme-induced oxidative end organ damage 30 , as well as in the PHZinduced hemolysis and sickle cell disease models ( Supplementary  Fig. 16b) . Finally, the clinical manifestations of inadequately cleared, stressed erythrocytes by FPN1 + tMΦs were phenocopied in mice challenged with stressed erythrocytes whose macrophages lacked FPN1 (Supplementary Fig. 17a,b) 31 , and they were ameliorated in a rescue experiment using LysM-specific, FPN1-deficient mice that received stressed erythrocytes (Supplementary Fig. 17c) . These findings indicate that hepatic recruitment of Ly-6C high monocytes and their differentiation into iron-recycling macrophages preserves organismal homeostasis during fluctuations of erythrocyte integrity.
In summary, we show that Ly-6C high monocytes and their progeny propagate on-demand, high-capacity erythrophagocytosis, and iron recycling. This liver-specific phenomenon is transient, dynamic, requires cell-intrinsic and environmental triggers, and controls iron homeostasis during erythrocyte damage (Supplementary Fig. 18 ). Understanding and eventually harnessing this mechanism may help to treat persons with abnormally heightened erythrocyte elimination due to sepsis, various forms of inflammation, frequent blood transfusions, or inborn or acquired defects in erythrocyte stability.
MeTHods
Methods and any associated references are available in the online version of the paper. Accession codes. Gene Expression Omnibus: Genome-wide expression data were deposited in the GEO repository under GSE77106. Fig. 2a ). Spleens were removed with the use of electrocauterization. Delivery of RBCs. RBC were isolated and adjusted to 17.5 g/dl hemoglobin, as described above. 400 µl per mouse were injected i.v. This amount of RBC delivery in mice corresponds to the transfusion of two units of packed RBCs in humans. Ki20227 injection. In some experiments, RBC transfer was accompanied by subcutaneous (s.c.) injection of the c-fms tyrosine kinase inhibitor Ki20227 at 50 mg/kg bodyweight (Tocris Biosciences, Bristol, UK). DAPTA and RS504393 injection. In some experiments, RBC transfer was accompanied by intraperitoneal (i.p.) injection of the Ccr2 antagonist RS504393 at 1 mg/kg body weight, dissolved in DMSO (Tocris Biosciences, Bristol, UK), and the Ccr5 antagonist DAPTA at 2 mg/kg body weight (Tocris Biosciences, Bristol, UK), dissolved in sterile water.
Both antagonists were administered again 6 h after sRBC transfer. SnPP-IX injection. In some experiments, RBC transfer was accompanied by i.p injection of the Hmox1 inhibitor SnPP-IX at 0.5 mg/kg body weight (Cayman Chemical, Ann Arbor, MI, USA). SnPP-IX was dissolved in 0.2 M NaOH, and the pH was adjusted to 7.40 with 1 M HCl. SnPP-IX was administered every 8 h, starting 30 min before sRBC transfer. Irradiation. In some experiments, mice were lethally radiated (10 Gy), but not reconstituted, with donor bone marrow cells for 10 d. Adoptive transfer. Ly-6C high and Ly-6C low monocytes were isolated by flow assisted cell sorting (FACS) from spleen or bone marrow of GFP + mice and 1 × 10 6 cells/mouse were injected i.v., followed by an additional sRBC injection. Parabiosis. Mice were joined in parabiosis, as previously described 32 . In brief, the opposing lateral sides of mice were shaved, skin incisions made from behind the ear to the tail, and the skin was bluntly detached from the subcutaneous fascia over a width of about 1 cm. At the laterally exposed areas of each parabiont, a 1-cm long incision of the peritoneum was made, and the corresponding edges were sutured together, joining the two peritoneal cavities. Finally, the parabionts were joined by suturing the corresponding scapulas and the skin with Ethylon 5-0 (Ethicon, Albuquerque, NM, USA). Both parabionts were injected in parallel with 400 µl sRBCs or saline as controls. Hemolytic anemia model involving PHZ. C57BL/6J WT mice were administered 2 mg/ mouse phenylhydrazine (PHZ; from Sigma-Aldrich, St. Louis, MO, USA) dissolved in 200 µl PBS i.p. 3 d after injection, peripheral blood was drawn from the cheek and measured for RBC content on a VetScan hematology analyzer (Abaxis Veterinary Diagnostics, Union City, CA, USA). Liver was excised after vascular perfusion with 20 ml sterile PBS, minced, and strained through a 40-µm nylon mesh (BD Bioscience, San Jose, CA, USA). The single-cell suspension was then stained with antibodies for flow-cytometric analysis. Brucella abortus-induced anemia model. To induce anemia, animals were injected i.p. with 1 × 10 9 particles per mouse of a commercially heat-killed B. abortus preparation (strain 1119-3; US Department of Agriculture, Animal and Plant Health Inspection Service, National Veterinary Services Laboratories, San Francisco, CA, USA). Control mice were injected i.p. with normal saline. During the experiments, mice were studied on days 0, 2, and 9 after injection. Sickle cell anemia model. Unless otherwise indicated, sickle cell disease mice and transgenic controls were studied in steady state. Lineage-tracing experiments: radiation-free bone marrow chimeras. 2-3-month-old WT mice were treated with low-dose busulfan (Busilvex, purchased from Pierre Fabre, Freiburg, Germany; 10 mg/kg, i.p.) and transplanted with 50-70 × 10 6 bone marrow cells obtained from GFP + mice 3 d later. Blood leukocyte chimerism (GFP positivity) was tested every week, and typically reached 50-90% among Ly-6C high monocytes. 3 weeks after bone marrow transplantation, mice were treated with sRBC or PBS and euthanized 4-7 days later; the chimerism of organ-resident myelocytes was checked with flow cytometry with co-staining for lineage and myeloid cell markers. tdTomato mice. Pregnant Cx3cr1-CreERT2 mice (mated with R26-tdT) were injected s.c. with tamoxifen (Sigma-Aldrich, 8 mg/animal in 400 µl corn oil) on days E13.5 and 15.5 to induce tdTomato expression in embryonic monocytes/macrophages. Pups were derived by Cesarean cut on day E21 and placed with nursing FVB/N dams. The Cx3cr1 CreERT2 ;R26-tdT pups were distinguished from the genuine litter by coat color. At the age of 10 weeks (P70), mice were transplanted with GFP bone marrow after busulfan pre-conditioning (see 'Radiation-free bone marrow chimeras') and challenged with sRBCs or PBS as described above (P91). Chimerism and tdTomato expression among blood leukocytes and organ-resident myelocytes was determined by flow cytometry. FPN1-deficient rescue experiments: LysM Cre/+ Slc40a1 fl/fl mice were treated with busulfan and transplanted with either LysM +/+ Slc40a1 fl/fl (WT) or LysM Cre/+ Slc40a1 fl/fl (FPN1 −/− ) bone marrow cells, as described above for WT mice. 3 weeks after transplantation, mice were infused with sRBCs and euthanized 16 h later. Serum and organ samples were collected and processed for liver and kidney function parameters and histology.
Mouse cells. Collection. Peripheral blood was collected by retroorbital bleeding with heparinized capillaries and, where appropriate, erythrocytes were lysed in RBC Lysis buffer (BioLegend, San Diego, CA, USA). Spleen and liver were excised after vascular perfusion with 20 ml sterile PBS. Organs were minced and strained through a 40-µm nylon mesh (BD Biosciences, San Jose, CA, USA). To increase the yield of hepatic macrophages, minced liver npg tissue was digested in 450 U/ml collagenase I, 60 U/ml DNase I and 60 U/ml hyaluronidase (Sigma-Aldrich, St. Louis, MO, USA) in PBS for 20 min at 37 °C while shaking. Cells were counted in a Neubauer chamber. Sorting. Mouse monocytes, macrophages, neutrophils, B cells and T cells from blood, spleen and liver homogenates were isolated by FACS with a FACS Aria II cell sorter. For adoptive transfer and culture experiments, mouse spleen homogenates were enriched for monocytes before FACS. In brief, splenocytes were incubated with 1 µl anti-CD11b (clone M1/70, BD Bioscience, San Jose, CA, USA) or anti-CD115 Ab (clone AFS98, ebioscience, San Diego, CA, USA) per 1 × 10 8 cells in sterile 2% FBS, 0.5% BSA in PBS for 30 min on ice, followed by MACS bead incubation and positive selection with a Midi MACS separator and LS column (all from Miltenyi, Bergisch Gladbach, Germany), according to the manufacturer's instructions. KC sorting in lineage-tracing experiments.
To maximize the yield of KCs, animals were perfused with Liberase (Roche, Mannheim, Germany) according to a published protocol 33 . The obtained single-cell suspension was centrifuged at 30g for 3 min to pellet hepatocytes, and the supernatants were centrifuged at 300g for 5 min to pellet the nonparenchymal fraction. The pellets were stained for Lineage (CD3, CD19, Ly-6G, NK1.1), CD45, CD11b, and F4/80 markers. In the case of marrow-transplanted WT mice, GFP + and GFP − KC were sorted from PBS-and sRBC-transfused mice. In the case of Cx3cr1 CreERT2 ;R26-tdT mice infused with sRBCs, tdTomato + GFP − (eKC) and tdTomato-GFP + mKCs were sorted into cooled 0.5 ml Eppendorf tubes containing 350 µl RLT Buffer (Qiagen, Hilden, Germany), with the addition of 1:100 β-mercaptoethanol. The amount of the sorted eKCs and mKCs was 5 × 10 4 cells per tube; at least three such tubes were collected per animal and pooled in the course of RNA isolation.
Human cells. Collection. Five people (one female, four males) undergoing cardiac surgery with the necessity for extracorporal circulation in the form of cardiopulmonary bypass (CPB) involving the Cell Saver autologous blood recovery system (Haemonetics Corporation, Braintree, MA, USA) were enrolled in an observational study approved by Partners Human Research Committee (Protocol No. 2013P002596/MGH). Written informed consent was obtained in accordance with the Declaration of Helsinki from these persons. Indications for cardiac surgery were aortic valve replacement (n = 3), aortic valve replacement and concurrent coronary artery bypass grafting (n = 1), and repair of an aneurysm of the aortic sinus (n = 1). A mean volume of 755 ml of cell saver, including autologous RBC but no packed RBCs, were transfused in the course of surgeries that had a mean duration of 242 min and a mean CBP time of 105 min. Peripheral blood samples were taken before, 15 min after, and 4 h after extracorporal circulation. Sorting. Human monocytes were isolated by FACS with a FACS Aria II cell sorter (BD Biosciences). Human peripheral blood mononuclear cells (hPBMCs) were enriched for monocytes before FACS. PBMCs were isolated from heparinized whole blood by the use of Ficoll density gradient centrifugation. For further enrichment, hPBMCs were incubated with 2 µl anti-HLA-DR (clone L243, BD Biosciences) or 2 µl anti-CD14 (clone MP9, BD Biosciences) per 1 × 10 8 cells in sterile 2% FBS, 0.5% BSA in PBS for 30 min on ice, followed by MACS bead incubation and positive selection with a Midi MACS separator and LS column, according to the manufacturer's instructions.
Flow cytometry. Cell suspensions were stained in PBS supplemented with sterile 2% FBS and 0.5% BSA. The following monoclonal antibodies were used for murine flow cytometric analysis (see Supplementary Table 1 for dilutions): anti-Ly-6C (clone AL-21, BD Biosciences, San Jose, CA, USA), anti-CD45.1 (clone A20, BioLegend, San Diego, CA, USA), anti-CD45.2 (clone 104, BD Biosciences), anti-CD3e (clone 145-2C11, ebioscience, San Diego, CA, USA), anti-CD90.2 (clone 53-2.1, BD Biosciences), anti-CD19 (clone 6D5, BioLegend), anti-B220 (clone RA3-6B2, BD Biosciences), anti-MHCII (clone AF6-120.1, BD Biosciences), anti-F4/80 (clone BM8, BioLegend), anti-CD49b (clone DX5, BD Biosciences), anti-NK1.1 (clone PK136, BD Biosciences), anti-Ly-6G (clone 1A8, BD Biosciences), anti-CD11b (clone M1/70, BD Biosciences), anti-CD11c (clone HL3, BD Biosciences), anti-Ter119 (clone Ter-119, BD Biosciences), anti-CD115 (clone AFS98, ebioscience), anti-mMer (MerTK, clone 108928, R&D), anti-mFcgammRI (clone 290322, R&D), anti-CD14 (Sa14-2, BioLegend), anti-CD36 (HM36,
